Literature DB >> 1321402

Functional interaction of p53 with HPV18 E6, c-myc and H-ras in 3T3 cells.

T M Chen1, V Defendi.   

Abstract

Wild-type (wt) p53 has been suggested to be the product of a tumor-suppressor gene. Recently, it has been shown that the E6 oncoproteins of human papillomavirus (HPV) types 16 and 18, like the SV40 large T antigen, are physically associated with wt p53. We have investigated the functional interaction of wt p53 with the viral oncogene products of HPV16 and 18 and with cellular oncogenes by transfection of NIH3T3 cells with p53 wt alone or with several oncogene(s). We found that over-expression of HPV18 E6, c-myc or activated H-ras, like SV40 large T, can partially overcome the growth-inhibitory effect of wt p53 in NIH3T3 cells, while HPV16 E6 and E7, HPV18 E7, k-fgf, c-fos and mutant (mt) p53 do not. Further studies indicate that HPV18 E6 and c-myc can overcome the antiproliferative effect, but not the antitransforming effect, of wt p53, while activated H-ras can overcome both the antiproliferative and antitransforming effects of wt p53. These data show evidence of a functional interaction between HPV18 E6 and wt p53, and suggest that the cooperation of HPV E6 and cellular oncogenes c-myc and H-ras, which are activated in several cases of human cervical cancers, may be necessary to overcome completely the anti-oncogenic function of p53 in the development of these tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321402

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Hepatitis C virus inhibits DNA damage repair through reactive oxygen and nitrogen species and by interfering with the ATM-NBS1/Mre11/Rad50 DNA repair pathway in monocytes and hepatocytes.

Authors:  Keigo Machida; George McNamara; Kevin T-H Cheng; Jeffrey Huang; Chun-Hsiang Wang; Lucio Comai; Jing-Hsiung James Ou; Michael M C Lai
Journal:  J Immunol       Date:  2010-10-25       Impact factor: 5.422

2.  Association of HPV with genetic and epigenetic alterations in colorectal adenocarcinoma from Indian population.

Authors:  Ruhina S Laskar; Fazlur R Talukdar; Javed H Choudhury; Seram Anil Singh; Sharbadeb Kundu; Bishal Dhar; Rosy Mondal; Sankar Kumar Ghosh
Journal:  Tumour Biol       Date:  2015-02-03

3.  Tumor-initiating stem-like cells and drug resistance: carcinogenesis through Toll-like receptors, environmental factors, and virus.

Authors:  Keigo Machida
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

Review 4.  Human papillomaviruses and cervical neoplasia. II. Interaction of HPV with other factors.

Authors:  C S Herrington
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

5.  Immunohistochemical study of β-catenin and functionally related molecular markers in tongue squamous cell carcinoma and its correlation with cellular proliferation.

Authors:  Xia Yun; Lihong Wang; Lei Cao; Norihiko Okada; Yoshio Miki
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

6.  PML, a growth suppressor disrupted in acute promyelocytic leukemia.

Authors:  Z M Mu; K V Chin; J H Liu; G Lozano; K S Chang
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

7.  Significance of P53 in human thyroid tumors.

Authors:  D Simon; P E Goretzki; V Gorelev; B Ebling; E Reishaus; J Lyons; H Haubruck; H D Röher
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

8.  p53-dependent activation of the mouse MCK gene promoter: identification of a novel p53-responsive sequence and evidence for cooperation between distinct p53 binding sites.

Authors:  P Jackson; M Shield; J Buskin; S Hawkes; M Reed; K Perrem; S D Hauschka; A Braithwaite
Journal:  Gene Expr       Date:  1995

9.  Biomarkers in cervical cancer.

Authors:  Eun-Kyoung Yim; Jong-Sup Park
Journal:  Biomark Insights       Date:  2007-02-07

10.  Evaluation of the significance of polyamines and their oxidases in the aetiology of human cervical carcinoma.

Authors:  C Fernandez; R M Sharrard; M Talbot; B D Reed; N Monks
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.